A Pivotal Study of Domatinostat (4SC-202) in Combination with avelumab Refractory Patients with Advanced Merkel Cell Carcinoma (MCC)
Phase of Trial: Phase III
Latest Information Update: 21 Oct 2019
Price : $35 *
At a glance
- Drugs Avelumab (Primary) ; Domatinostat (Primary)
- Indications Merkel cell carcinoma
- Focus Registrational; Therapeutic Use
- Acronyms MERKLIN 2
- Sponsors 4SC
- 21 Oct 2019 According to a 4SC media release, design of MERKLIN 1 and MERKLIN 2 studies will be presented at the 1st International Symposium on Merkel Cell Carcinoma by Dr. Rene Bartz. The trial is planned to initiate in Q4,2020.
- 08 Aug 2019 According to a 4SC media release, the company plans to start this trial in late 2019.
- 08 Aug 2019 According to a 4SC media release, initial top-line data is expected in the first half of 2021